Alterity Therapeutics (ASX:ATH) has disclosed that it has reached alignment with the US Food and Drug Administration on the key elements of the design and potential registrational pathway for a Phase 3 trial of its lead drug candidate ATH434 in Multiple System Atrophy, according to the Chairman's address delivered at the company's 2026 Annual General Meeting.
Key Points
- Alterity has achieved alignment with the FDA on the key design elements and potential registrational pathway for a Phase 3 trial of ATH434 in Multiple System Atrophy
- The company reported A$41.3 million in cash as at the end of September
- A new US composition of matter patent has been secured, extending intellectual property protection for ATH434 to 2045
- The company successfully produced its first registration batch of ATH434
- Ann Cunningham joined the Board in April, bringing pharmaceutical and commercial experience in neurology
FDA Alignment on ATH434 Phase 3 Registrational Pathway
Chairman Julian Babarczy, who joined the Board following last year's AGM and was addressing his first AGM in the role, stated that following a series of constructive interactions with the FDA, Alterity now has alignment on the key elements of the design and potential registrational pathway for a Phase 3 trial of ATH434 in Multiple System Atrophy. The chairman described this as providing a clear framework for the next phase of development. Further detail on the FDA feedback and Phase 3 trial design was noted as being covered separately by the company's other presenter at the meeting.
Manufacturing Milestone and Intellectual Property
According to the filing, Alterity made progress in manufacturing during the period, including the successful production of its first registration batch of ATH434. The company also strengthened its intellectual property position through the grant of a new US composition of matter patent, which extends protection for ATH434 to 2045. The chairman's address also noted that further analyses of Phase 2 results, along with publications and presentations at major international scientific conferences, have added to the scientific evidence base and informed the design of the pivotal trial.
Cash Position and Phase 3 Funding Priorities
The filing disclosed that Alterity finished September with A$41.3 million in cash. The chairman stated that Phase 3 will require a substantial financial commitment and that securing appropriate funding and development structure remains a key priority for the Board. The company said it continues to evaluate a range of alternatives, including potential pharmaceutical partnerships and other strategic and capital funding options. Operational preparations for the Phase 3 trial were described as already underway, with further detail noted as forthcoming in the meeting presentation.




Please wait processing your request...